None of the 29 investors followed here reported a position in KLDO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a KLDO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for KLDO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 900.0 | -90.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0% |
| 2024 | 0.0 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +900.0% |
| 2023 | -40.0 | -33.3 | 0.0 | 0.0 | -95.0 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -90.0 | −98.0% |
| 2022 | -26.4 | -15.3 | 10.7 | -97.0 | 66.5 | -25.3 | -94.9 | -65.6 | 9.1 | -8.3 | 0.0 | -54.5 | −100.0% |
| 2021 | 64.3 | -40.3 | -9.3 | -2.6 | -9.0 | 3.6 | -27.0 | 13.1 | -11.1 | -21.2 | -16.5 | -33.4 | −73.7% |
| 2020 | 70.9 | -30.4 | 3.0 | 5.9 | 10.9 | 2.9 | -19.7 | 5.4 | 76.0 | -44.8 | 29.0 | 15.5 | +81.3% |
| 2019 | 1.9 | -1.0 | 9.2 | -26.0 | -33.9 | 22.0 | -19.6 | -22.2 | 48.6 | -42.4 | −64.7% |
No analyst coverage for this instrument.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic immune disease, chronic obstructive pulmonary disease pathogens, and immuno-oncology. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
No recent headlines.